Magdaleno Rodriguez Daniel Roberto, Avila Lamadrid Pamela Georgina, Sanchez Flores Jessica Alejandra, Cortes Moreno Gabriela Yanet and Lara Padilla Eleazar
Escuela Superior de Medicina del Instituto Politecnico Nacional, Mexico
Scientific Tracks Abstracts: J Diabetes Metab
Obesity has become a public global health, we can not lose sight that this disease has reached epidemic global proportions, which is why the World Health Organization (WHO by the acronym in English) calls obesity as the epidemic of the century. The purpose of this study was to evaluate the efficacy and safety of the combination of silymarin, selenomethionine and alphalipoecoico acid in adult patients with non alcoholic fatty liver using different dosages, comparing changes in patients receiving doses every 8 hours against the patients that received doses every 12 hours. It was evaluated the biochemical changes through blood, morphological determinations by ultrasound and anthropometric measurements. It was a longitudinal, prospective and comparative study during 12 weeks. This study was conducted under 88 exogenous obese patients, aged between 18 and 60 years of both sexs with Body Mass Index (BMI by the acronym in English) between 30 and 45 kg/m2 and diagnosed with fatty liver confirmed by ultrasound with sub-clinical alterations in liver enzymes. Patients were randomized into two groups of 44 subjects each and were administered for three months the combination of silymarin, selenomethionine and alphalipoecoico acid with dosage of one capsule every 8 hours (group 1) and every 12 hours (group 2).
Daniel Roberto Magdaleno Rodriguez is Mexican medical student of Superior School of Medicine (Escuela Superior de Medicina) at Instituto Politécnico Nacional. He is a junior researcher who has been working at the obesity center of the School since 2013 on different research lines regargding obesity, diabetes, fatty liver, metabolic syndrome and hipertension. His most important recent research is focused on drug effectiveness and security for obesity and fatty livertreatment. CEO and founder of AIMEDS A.C.
